Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
@Dalestar
This rang a bell, and it does seem so:
https://www.jobs.ac.uk/job/CBY342?
I'm not sure if it's this person as I don't have a linkedin account to see their full profile:
https://uk.linkedin.com/in/abdullah-al-omari-6a5429128
Did I dream it or did we advertise for a Car-T expert a while ago?
Www.Glymab.com mmm interesting
hi Bermudashorts
I always welcome your sage advice on these issues. I am also of the opinion that there has been a change in strategy and if my hunch is right it means LD is now very comfortable with her new role. It is a feeling rather than fact obviously but Covidity looks to be moving serenely towards a Booster trial in the UK, I was extremely pleased with the upgrade on the SCIB1 trial and we causiously await ModiTope doing its thing and being proven to work in humans. That will be a good day when we know it works .....
Scancell may already be in talks re-Covidity and BionTech maybe be ringing every other day to know if ModiFy is producing their much needed TCR 'T-Cells'.
There just seems to be a lot of confidence in the way the GlyMabs RNS was framed. Success on all fronts plus cash coming in = 100 employees by end 2023.
Its as seen in my Crystal Ball.... lol
Chester.
I agree Bermuda they don’t understand Glymab is a product!!!
H2 coming from Friday.
Buckle up I say :-)
Bermuda
I don't think it is a change of strategy, more a clarification of strategy.
I'm pretty sure Lindy has said in the past that GlyMabs would be be progressed to the clinic either by partnership or by Scancell alone.
But I agree that another interview would have been helpful to fill in some of the details.
Chester,
If Scancell want to scale up to over 100 staff with 4 ongoing trials then they're going to have to put in some addional infrastructure and also support for LD. I don't believe that it's possible to run a company of that size with a part time CEO, especially one with a scientific rather than business background and of course, there would also be an impact on cash burn.
I wish LD had done some media following the glycan mAb RNS last week. There has been a clear change in strategy and it would be good to have a more detailed explanation covering the commercial and financial implications.
We also now have the staff, not exactly sure where we are on numbers but we must be heading over 30 and heading for 40.
Added to that we also have the new office suites in Oxford where all the advances towards the clinic will be coordinated.
Thinking towards the future I can see Scancell employing 100 and running 4 trials covering 10 different cancers by the end of 2023.
Chester.
Last sentence, I meant to say
There are some who see it differently!
I entirely agree bobbust.
In fact, if you make yet another advance in the science, why not make the decision to move it towards the clinic. This is on the proviso that Scancell have the expertise to take it into to the clinic. This, together with help from their partner, is clearly the case with this latest development.
The CAR-T and ADC avenues are not obviously within Scancell's area of expertise and so they are actively seeking partnerships for these areas. But partnerships will come only when Lindy has demonstrated, to her satisfaction, that Scancell have done the groundwork to prove the potential in these areas.
Exactly when the time to deal arrives, I reckon we can trust Lindy to decide on that. She certainly isn't going to take low offers. Perhaps she wants the Avidimab evidence of Covidity to arrive first.
All in all, what a great situation Scancell now find themselves in.
With the current situation, Scancell are clearly looking for the best possible deals
The are some
We had as 31 oct £35m in cash
loss for 6m £4m
why not develop in house
It makes everthing more valuable!!!
things are now going at a pace now they have a decent amount of cash